The association between circulating CD34+CD133+ cells and the risk of AD in the context of genetic background

rs4144611 (KIRREL3)rs580382 (KIRREL3)rs61619102 (EXOC6B)
GenotypeCD34+CD133+ cutoffsHR
(95% CI)
P valueGenotypeCD34+CD133+ cutoffsHR
(95% CI)
P valueGenotypeCD34+CD133+ cutoffsHR
(95% CI)
P value
TT25%0.18 (0.07–0.46)3.3 × 10-4*CC25%0.21 (0.09–0.47)1.7 × 10-4*CC25%0.48 (0.26–0.88)0.02*
50%0.11 (0.03–0.42)0.001*50%0.16 (0.05–0.47)9.6 × 10-4*50%0.38 (0.19–0.74)0.005*
75%N/A (zero AD)0.006a*75%N/A (zero AD)0.002a*75%0.25 (0.08–0.81)0.02*
GG + TG25%1.02 (0.46–2.25)0.96TT + CT25%1.80 (0.68–4.82)0.24GG + GC25%2.22 (0.39–12.64)0.37
50%1.54 (0.76–3.15)0.2350%2.44 (1.07–5.56)0.03*50%12.38 (2.00–76.65)0.007*
75%1.39 (0.64–3.05)0.4175%1.80 (0.80–4.07)0.1675%5.68 (1.65–19.61)0.006*

Participants were first stratified into KIRREL3 rs4144611 TT vs. GG + TG; rs580382 CC vs. TT + CT as well as in EXOC6B rs61619102 CC vs. GG + GC genotype groups. Using Cox proportional hazards regression model, AD incidence was associated with (CD34+CD133+ cutoffs: 25%, 50%, and 75%) after adjusting for age, sex, years of education, APOE ɛ4, and PCs for each genotype group. a When CD34+CD133+ is higher than the 75% percentile, there are no AD cases among these genotypes, KIRREL3 rs4144611 TT, KIRREL3 rs580382 CC, and EXOC6B; * P value significant < 0.05